Quantinno Capital Management LP Raises Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Quantinno Capital Management LP raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 81.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 99,794 shares of the company’s stock after purchasing an additional 44,875 shares during the quarter. Quantinno Capital Management LP’s holdings in IDEXX Laboratories were worth $56,074,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Elyxium Wealth LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $3,666,459,000. State Street Corp increased its stake in shares of IDEXX Laboratories by 4.0% in the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after buying an additional 138,956 shares during the last quarter. J. Stern & Co. LLP increased its stake in shares of IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares during the last quarter. Geode Capital Management LLC raised its holdings in IDEXX Laboratories by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after acquiring an additional 86,263 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in IDEXX Laboratories by 13.8% in the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after acquiring an additional 181,955 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDXX stock opened at $569.46 on Thursday. The stock’s 50 day simple moving average is $557.25 and its 200 day simple moving average is $591.71. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The firm has a market cap of $44.92 billion, a P/E ratio of 41.93, a P/E/G ratio of 3.12 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company posted $2.91 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on IDXX shares. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Finally, UBS Group decreased their price target on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating for the company in a research note on Monday. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $749.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.